Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Adachi

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
International Immunology|February 4, 2021
Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in JapanTomohiro Takano, Takayuki Matsumura, Yu Adachi, et al.
Nature Communications|March 2, 2026
Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza virusesSaya Moriyama, Julia di Iulio, Fabrizia Zatta, et al.
Immunity|September 11, 2021
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable siteTaishi Onodera, Shunsuke Kita, Yu Adachi, et al.
Immunity|July 11, 2021
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variantsSaya Moriyama, Yu Adachi, Takashi Sato, et al.
Med (New York, N.Y.)|March 9, 2022
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variantsSho Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
HLA|March 18, 2021
Association of HLA-DRB1*09:01 with severe COVID-19Alitzel Anzurez, Izumi Naka, Shoji Miki, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
International Immunology|February 4, 2021
Myeloid cell dynamics correlating with clinical outcomes of severe COVID-19 in JapanTomohiro Takano, Takayuki Matsumura, Yu Adachi, et al.
Nature Communications|March 2, 2026
Potent efficacy of an NA-targeting antibody against a broad spectrum of H5N1 influenza virusesSaya Moriyama, Julia di Iulio, Fabrizia Zatta, et al.
Immunity|September 11, 2021
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable siteTaishi Onodera, Shunsuke Kita, Yu Adachi, et al.
Immunity|July 11, 2021
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variantsSaya Moriyama, Yu Adachi, Takashi Sato, et al.
Med (New York, N.Y.)|March 9, 2022
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variantsSho Miyamoto, Takeshi Arashiro, Yu Adachi, et al.
HLA|March 18, 2021
Association of HLA-DRB1*09:01 with severe COVID-19Alitzel Anzurez, Izumi Naka, Shoji Miki, et al.
Pageof 5